Omori Kazuno相关文献与解析，生知库 | 链接生命科学的每一步

Roy Abhishek, Hoff Alexandra, Her Tracy K, Ariyaratne Gallage, GutiÃ©rrez Roberto-LeÃ³n, Tahawi M H D Noor, Rajagopalan Kamalnath Sankaran, Brown Matthew R, Omori Kazuno, Lewis-Brinkman Sean, Nguyen Thanh, Soto-GonzÃ¡lez Alondra, Peterson Quinn P, Matveyenko Aleksey V, Javeed Naureen

细胞生物学

囊泡

发表日期：2025

文献求助收藏

Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease

从传统贝特类药物换用培马贝特对合并慢性肾病的糖尿病患者的肾功能有益

期刊:Diabetes & Metabolism Journal

影响因子:8.5

doi:10.4093/dmj.2023.0370

Izumihara, Rimi; Nomoto, Hiroshi; Kito, Kenichi; Yamauchi, Yuki; Omori, Kazuno; Shibayama, Yui; Yanagiya, Shingo; Miya, Aika; Kameda, Hiraku; Cho, Kyu Yong; Nagai, So; Sakuma, Ichiro; Nakamura, Akinobu; Atsumi, Tatsuya

Severe infection including disseminated herpes zoster triggered by subclinical Cushing's disease: a case report

亚临床库欣病诱发的严重感染（包括播散性带状疱疹）：病例报告

期刊:BMC Endocrine Disorders

影响因子:3.3

doi:10.1186/s12902-021-00757-y

Yamauchi, Yuki; Kameda, Hiraku; Omori, Kazuno; Tani, Michio; Cho, Kyu Yong; Nakamura, Akinobu; Miyoshi, Hideaki; Tanaka, Shinya; Atsumi, Tatsuya

Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone

与吡格列酮相比，钠-葡萄糖协同转运蛋白2抑制剂达格列净对非酒精性脂肪肝具有有利作用

期刊:Journal of Diabetes Investigation

影响因子:3

doi:10.1111/jdi.13457

Cho, Kyu Yong; Nakamura, Akinobu; Omori, Kazuno; Takase, Takahiro; Miya, Aika; Yamamoto, Kohei; Nomoto, Hiroshi; Kameda, Hiraku; Taneda, Shinji; Kurihara, Yoshio; Aoki, Shin; Atsumi, Tatsuya; Miyoshi, Hideaki

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin

内源性胰岛素分泌对接受卡格列净联合替格列汀治疗的日本2型糖尿病患者血糖波动改善的影响

期刊:Journal of Diabetes Investigation

影响因子:3

doi:10.1111/jdi.13479

Miya, Aika; Nakamura, Akinobu; Cho, Kyu Yong; Kawata, Shinichiro; Nomoto, Hiroshi; Nagai, So; Sugawara, Hajime; Taneda, Shinji; Tsuchida, Kazuhisa; Omori, Kazuno; Yokoyama, Hiroki; Takeuchi, Jun; Aoki, Shin; Kurihara, Yoshio; Atsumi, Tatsuya; Miyoshi, Hideaki

Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study

卡格列净联合替格列汀可改善血糖达标时间和餐后高血糖：CALMER 研究的二次分析

期刊:Journal of Diabetes Investigation

影响因子:3

doi:10.1111/jdi.13498

Cho, Kyu Yong; Nomoto, Hiroshi; Nakamura, Akinobu; Kawata, Shinichiro; Sugawara, Hajime; Takeuchi, Jun; Nagai, So; Omori, Kazuno; Tsuchida, Kazuhisa; Miya, Aika; Shigesawa, Ikumi; Tsuchida, Kenichi; Yanagiya, Shingo; Kameda, Hiraku; Yokoyama, Hiroki; Taneda, Shinji; Kurihara, Yoshio; Aoki, Shin; Nishimoto, Naoki; Atsumi, Tatsuya; Miyoshi, Hideaki

发表日期：2021

文献求助收藏

Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study)

钠-葡萄糖协同转运蛋白-2抑制剂卡格列净联合二肽基肽酶-4抑制剂替格列汀对血糖波动的有利影响：一项开放标签、前瞻性、随机、平行组比较试验（CALMER研究）

期刊:Diabetes Obesity & Metabolism

影响因子:5.7

doi:10.1111/dom.13879

Cho, Kyu Yong; Nomoto, Hiroshi; Nakamura, Akinobu; Kawata, Shinichiro; Sugawara, Hajime; Takeuchi, Jun; Nagai, So; Tsuchida, Kazuhisa; Omori, Kazuno; Yokoyama, Hiroki; Manda, Naoki; Kurihara, Yoshio; Aoki, Shin; Atsumi, Tatsuya; Miyoshi, Hideaki

发表日期：2020

文献求助收藏

Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study

二肽基肽酶-4抑制剂换用卢格列净对2型糖尿病患者夜间血压的影响：一项多中心、前瞻性、随机、开放标签、盲法终点平行组比较研究方案

期刊:BMJ Open

影响因子:2.3

doi:10.1136/bmjopen-2019-034883

Kameda, Reina; Nomoto, Hiroshi; Cho, Kyu Yong; Kawata, Shinichiro; Omori, Kazuno; Takeuchi, Jun; Nagai, So; Kurihara, Yoshio; Aoki, Shin; Nakamura, Akinobu; Atsumi, Tatsuya; Miyoshi, Hideaki

Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial

吡格列酮换用钠-葡萄糖协同转运蛋白2抑制剂达格列净对2型糖尿病患者体重和代谢相关因素的影响：一项开放标签、前瞻性、随机、平行组对照试验

期刊:Diabetes Obesity & Metabolism

影响因子:5.7

doi:10.1111/dom.13557

Cho, Kyu Yong; Nakamura, Akinobu; Omori, Kazuno; Takase, Takahiro; Miya, Aika; Manda, Naoki; Kurihara, Yoshio; Aoki, Shin; Atsumi, Tatsuya; Miyoshi, Hideaki

Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea

瑞格列奈降低老年 2 型糖尿病患者血糖波动：瑞格列奈与磺脲类药物的随机对照试验

期刊:Journal of Diabetes Investigation

影响因子:3

doi:10.1111/jdi.12889

Omori, Kazuno; Nomoto, Hiroshi; Nakamura, Akinobu; Takase, Takahiro; Cho, Kyu Yong; Ono, Kota; Manda, Naoki; Kurihara, Yoshio; Aoki, Shin; Atsumi, Tatsuya; Miyoshi, Hideaki

Lipotoxicity Induces Î²-cell Small Extracellular Vesicle-Mediated Î²-cell Dysfunction in Male Mice.

脂毒性诱导雄性小鼠β细胞小细胞外囊泡介导的β细胞功能障碍

Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease

从传统贝特类药物换用培马贝特对合并慢性肾病的糖尿病患者的肾功能有益

Severe infection including disseminated herpes zoster triggered by subclinical Cushing's disease: a case report

亚临床库欣病诱发的严重感染（包括播散性带状疱疹）：病例报告

Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone

与吡格列酮相比，钠-葡萄糖协同转运蛋白2抑制剂达格列净对非酒精性脂肪肝具有有利作用

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin

内源性胰岛素分泌对接受卡格列净联合替格列汀治疗的日本2型糖尿病患者血糖波动改善的影响

Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study

卡格列净联合替格列汀可改善血糖达标时间和餐后高血糖：CALMER 研究的二次分析

Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study)

钠-葡萄糖协同转运蛋白-2抑制剂卡格列净联合二肽基肽酶-4抑制剂替格列汀对血糖波动的有利影响：一项开放标签、前瞻性、随机、平行组比较试验（CALMER研究）

Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study

二肽基肽酶-4抑制剂换用卢格列净对2型糖尿病患者夜间血压的影响：一项多中心、前瞻性、随机、开放标签、盲法终点平行组比较研究方案

Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial

吡格列酮换用钠-葡萄糖协同转运蛋白2抑制剂达格列净对2型糖尿病患者体重和代谢相关因素的影响：一项开放标签、前瞻性、随机、平行组对照试验

Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea

瑞格列奈降低老年 2 型糖尿病患者血糖波动：瑞格列奈与磺脲类药物的随机对照试验